Pharmaceuticals, Biotechnology and Life Sciences
“The new funds we are raising will support the ongoing progress of these important assets as well as the rest of our pipeline and we remain very positive about Redx’s prospects.”
Cancer Research UK (CR UK), the world’s largest not-for-profit cancer research organization, has today announced that six leading U.S. scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research.
Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.
Neurocrine Biosciences has made a deal with BIAL to develop and sell Ongentys opicapone inhibitor for Parkinson’s patients, in North America.
Amgen co-founder Dr. Joseph Rubinfeld, who was an independet director of Amarantus BioScience Holdings has died.
Canadian commercial dermatology company Crescita Therapeutics has named its Corporate Controller Ms. Muneerah Kanji as Interim Chief Financial Officer.
Aytu BioScience, a drugmaker focused on urology products, has increased gross product sales by 47% from the quarter ended September 30, 2016 to the quarter ended December 31, 2016, from $925,000 to $1,358,000, getting its first ever $1M-plus quarter sales.
Hybrigenics has given an update on the Phase II clinical study of inecalcitol in chronic myeloid leukemia (CML) administered in addition to imatinib, the reference inhibitor of BCR-ABL kinase used as standard of care for CML.
The Muscular Dystrophy Association said yesterday it welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (Emflaza), developed by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.
NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.